These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 8486592)

  • 1. The abrupt discontinuation of fluvoxamine in patients with panic disorder.
    Black DW; Wesner R; Gabel J
    J Clin Psychiatry; 1993 Apr; 54(4):146-9. PubMed ID: 8486592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prospective evaluation of antidepressant discontinuation].
    Mourad I; Lejoyeux M; Adès J
    Encephale; 1998; 24(3):215-22. PubMed ID: 9696914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiological data of patients treated with fluvoxamine: results from a 12 week non-comparative multicentre study.
    Dewulf L; Hendrickx B; Lesaffre E
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():67-72. PubMed ID: 7622826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Abrupt discontinuation of alprazolam and cognitive style in patients with panic disorder: early effects on mood, performance, and vital signs.
    Uhlenhuth EH; Starcevic V; Qualls C; Antal EJ; Matuzas W; Javaid JI; Barnhill J
    J Clin Psychopharmacol; 2006 Oct; 26(5):519-23. PubMed ID: 16974197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder.
    Perahia DG; Kajdasz DK; Desaiah D; Haddad PM
    J Affect Disord; 2005 Dec; 89(1-3):207-12. PubMed ID: 16266753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Norplant-associated major depression and panic disorder.
    Wagner KD; Berenson AB
    J Clin Psychiatry; 1994 Nov; 55(11):478-80. PubMed ID: 7989280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with or without agoraphobia.
    Bakish D; Hooper CL; Filteau MJ; Charbonneau Y; Fraser G; West DL; Thibaudeau C; Raine D
    Psychopharmacol Bull; 1996; 32(1):135-41. PubMed ID: 8927663
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind, placebo-controlled trial of two doses of abecarnil for geriatric anxiety.
    Small GW; Bystritsky A
    J Clin Psychiatry; 1997; 58 Suppl 11():24-9. PubMed ID: 9363045
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phenomenology and severity of major depression and comorbid lifetime anxiety disorders in primary medical care practice.
    Brown C; Schulberg HC; Shear MK
    Anxiety; 1996; 2(5):210-8. PubMed ID: 9160625
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The relation between anger management style, mood and somatic symptoms in anxiety disorders and somatoform disorders.
    Koh KB; Kim DK; Kim SY; Park JK; Han M
    Psychiatry Res; 2008 Sep; 160(3):372-9. PubMed ID: 18718675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapering clonazepam in patients with panic disorder after at least 3 years of treatment.
    Nardi AE; Freire RC; Valença AM; Amrein R; de Cerqueira AC; Lopes FL; Nascimento I; Mezzasalma MA; Veras AB; Sardinha A; de Carvalho MR; da Costa RT; Levitan MN; de-Melo-Neto VL; Soares-Filho GL; Versiani M
    J Clin Psychopharmacol; 2010 Jun; 30(3):290-3. PubMed ID: 20473065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Emergence of depressive symptoms during treatment for panic disorder with specific 5-hydroxytryptophan reuptake inhibitors.
    Fux M; Taub M; Zohar J
    Acta Psychiatr Scand; 1993 Oct; 88(4):235-7. PubMed ID: 8256637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena.
    Bhanji NH; Chouinard G; Kolivakis T; Margolese HC
    Can J Clin Pharmacol; 2006; 13(1):e69-74. PubMed ID: 16456219
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Morbidity of comorbid psychiatric diagnoses in the clinical presentation of panic disorder.
    Apfeldorf WJ; Spielman LA; Cloitre M; Heckelman L; Shear MK
    Depress Anxiety; 2000; 12(2):78-84. PubMed ID: 11091930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of levetiracetam on depression and anxiety in adult epileptic patients.
    Mazza M; Martini A; Scoppetta M; Mazza S
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):539-43. PubMed ID: 18031881
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Schneiderian first-rank symptoms associated with fluvoxamine treatment: a case report.
    Ueda N; Terao T; Ohmori O; Nakamura J
    Hum Psychopharmacol; 2003 Aug; 18(6):477-8. PubMed ID: 12923827
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.